Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers

Health Policy

Volumn 112, Issue 3, 2013, Pages 248-254

  Morgan, Steven G ^a   Thomson, Paige A ^a   Daw, Jamie R ^a   Friesen, Melissa K ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Canada; Prescription drugs; Reimbursement mechanisms; Risk sharing

Indexed keywords

PRESCRIPTION DRUG;

ARTICLE; CANADA; COST EFFECTIVENESS ANALYSIS; HEALTH CARE; HEALTH CARE POLICY; HOSPITAL CARE; INTERPERSONAL COMMUNICATION; POPULATION SIZE; REIMBURSEMENT; TELEPHONE INTERVIEW;

CANADA; PRESCRIPTION DRUGS; REIMBURSEMENT MECHANISMS; RISK SHARING;

ADMINISTRATIVE PERSONNEL; CANADA; CONTRACTS; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; FORMULARIES AS TOPIC; HUMANS; INTERVIEWS AS TOPIC; NEGOTIATING; POLICY MAKING; PRESCRIPTION DRUGS; REIMBURSEMENT MECHANISMS;

EID: 84887121716     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2013.05.022     Document Type: Article

References (36)

1. Carlson J.J., Sullivan S.D., Garrison L.P., Neumann P.J., Veenstra D.L. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010, 96(3):179-190.
2. Trueman P., Grainger D.L., Downs K.E. Coverage with evidence development: applications and issues. International Journal of Technology Assessment in Health Care 2010, 26(1):79-85.
3. Cheema P.K., Gavura S., Migus M., Godman B., Yeung L., Trudeau M.E. International variability in the reimbursement of cancer drugs by publically funded drug programs. Current Oncology 2012, 19(3):pe165-pe176.
4. Vogler S., Zimmermann N., Habl C., Piessnegger J., Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. Southern Med Review 2012, 5(1):38-46.
5. Adamski J., Godman B., Ofierska-Sujkowska G., Osińska B., Herholz H., Wendykowska K., et al. Risk sharing arrangements for pharmaceuticals: Potential considerations and recommendations for European payers. BMC Health Services Research 2010, 10:p153.
6. Neumann P.J., Chambers J.D., Simon F., Meckley L.M. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Affairs 2011, 30(12):2329-2337.
7. Marchildon G.P., Mossialos E., Allin S. Health systems in transition: Canada 2006, xiii:156. European Observatory on Health Systems and Policies, University of Toronto Press, Toronto.
8. Daw J.R., Morgan S.G. Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010. Health Policy 2012, 104(1):19-26.
9. Pomey M.-P., Forest P.-G., Palley H.A., Martin E. Public/private partnerships for prescription drug coverage: policy formulation and outcomes in Quebec's universal drug insurance program, with comparisons to the Medicare prescription drug program in the United States. Milbank Quarterly 2007, 85(3):469-498.
10. Mitton C.R., McMahon M., Morgan S., Gibson J. Centralized drug review processes: are they fair?. Social Science and Medicine 2006, 63(1):200-211.
11. Morgan S., Hanley G., Raymond C., Blais R. Breadth, depth and agreement among provincial formularies in Canada. Healthcare Policy 2009, 4(4):pe162-pe184.
12. Gamble J.-M., Weir D.L., Johnson J.A., Eurich D.T. Analysis of drug coverage before and after the implementation of Canada's Common Drug Review. Canadian Medical Association Journal 2011, 183(17):E1259-E1266.
13. Menon D., Stafinski T., Stuart G. Access to drugs for cancer - does where you live matter?. Canadian Journal of Public Health 2005, 96(6):454-458.
14. PMPRB Compendium of policies, guidelines and procedures 2011, Patented Medicine Prices Review Board, Ottawa.
15. Quebec G.O. Règlement sur les conditions de reconnaissance d'un fabricant de médicaments et d'un grossiste in A-29.01 2012.
16. Morgan S., Barer M., Agnew J. Whither seniors' pharmacare: lessons from (and for) Canada. Health Affairs 2003, 22(3):49-59.
17. Docteur E., Paris V., Moise P. Pharmaceutical pricing policies in a global market. Health policy studies (Paris, France) 2008, 215. Organisation for Economic Co-operation and Development, Paris.
18. Paris V., Docteur E. Pharmaceutical pricing and reimbursement policies in Canada, in OECD Health Working Papers 2007, Organisation for Economic Co-operation and Development, Paris.
19. Miles M.B., Huberman A.M. Qualitative data analysis: an expanded sourcebook 1994, Sage Publications, Thousand Oaks. 2nd ed.
20. Nason E., Sproule J. Industry-payor agreements for pharmaceuticals: backgrounder for roundtable 2011, Institute of Health Economics, Edmonton.
21. Sirrs S., Clarke J.T.R., Bichet D.G., Casey R., Lemoine K., Flowerdew G., et al. Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative. Molecular Genetics and Metabolism 2010, 99(4):367-373.
22. Auditor General of Ontario Audit of the drug programs activity of the Ministry of Health and Long-Term Care. Annual Report of the Provincial Auditor of Ontario 2001.
23. Transparent Drug System for Patients Act An act to amend the drug interchangeability and dispensing fee act and the Ontario Drug Benefit Act 2006.
24. Manitoba Health, Healthy Living Annual report 2006-2007 2008, Government of Manitoba, Winnipeg.
25. Alberta Health, Wellness Product listing agreement policy 2011, Government of Alberta, Edmonton.
26. Saskatchewan Health Product listing agreements 2011, Government of Saskatchewan, Regina. Drug Plan and Extended Benefits Branch (Ed.).
27. Pharmaceutical Services Division Progress on implementing the Auditor General's recommendations on managing PharmaCare 2008, BC Ministry of Health, Victoria.
28. Morgan S., Daw J., Thomson P. International best practices for negotiating 'Reimbursement Contracts' with price rebates from pharmaceutical companies. Health Affairs 2013, 32(4):771-777.
29. Seiter A. A practical approach to pharmaceutical policy, directions in development. Human development 2010, xxi:215. World Bank, Washington, DC.
30. Jaroslawski S., Toumi M. Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Services Research 2011, 11(1):p259.
31. Morgan S., Hanley G., McMahon M., Barer M. Influencing drug prices through formulary-based policies: lessons from New Zealand. Healthcare Policy 2007, 3(1):1-20.
32. CIHI Drug expenditure in Canada, 1985-2011 2012, Canadian Institute for Health Information, Ottawa.
33. Statistics Canada CANSIM, Table 384-0002 and Catalogue no. 13-213-PPB 2011, Available from:, [accessed 17.08.12]. http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/econ15-eng.htm.
34. Carbonneil C., Quentin F., Lee-Robin S.H. A common policy framework for evidence generation on promising health technologies. International Journal of Technology Assessment in Health Care 2009, 25(Suppl. S2):56-67.
35. Godman B., Paterson K., Malmstrom R.E., Selke G., Fagot J.P., Mrak J. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Review of Pharmacoeconomics & Outcomes Research 2012, 12(4):439-441.
36. Morel C.M., McGuire A., Mossialos E. The level of income appears to have no consistent bearing on pharmaceutical prices across countries. Health Affairs 2011, 30(8):1545-1552.